| ID Source | ID |
|---|---|
| PubMed CID | 441244 |
| CHEMBL ID | 1382627 |
| CHEBI ID | 9142 |
| SCHEMBL ID | 15633 |
| MeSH ID | M0019872 |
| Synonym |
|---|
| AC-3535 |
| silver(1+) [(4-aminophenyl)sulfonyl](pyrimidin-2-yl)azanide |
| CHEBI:9142 , |
| sulfadiazine silver salt |
| silver(1+) sulfadiazinate |
| silver sulfadiazinate |
| dermazin |
| flamazine |
| silver sulphadiazine |
| NSC625324 , |
| silvadene |
| benzenesulfonamide, 4-amino-n-2-pyrimidinyl-, monosilver(1+) salt |
| silver (4-aminophenyl)sulfonyl-pyrimidin-2-yl-azanide |
| SSD , |
| sulfadiazine silver |
| DB05245 |
| silvadene (tn) |
| sulfadiazine silver (jp17) |
| sulfadiazine, silver (usp) |
| D00433 |
| sulfanilamide, n(sup 1)-2-pyrimidinyl-, monosilver(1+) salt |
| geben |
| sulfadiazin, silbersalz |
| sulfadiazine, silver [usan] |
| nsc 625324 |
| n1-2-pyrimidinylsulfanilamide monosilver(1+) salt |
| 4-amino-n-(2-pyrimidinyl)benzenesulfonamide silver salt |
| sildaflo |
| silbertone |
| einecs 244-834-5 |
| (4-amino-n-pyrimidin-2-ylbenzenesulphonamidato-nn,o1)silver |
| silver, (4-amino-n-2-pyrimidinylbenzenesulfonamidato-nn,o1)- |
| sulfadiazine, silver |
| sulfafdiazine, silver |
| dermazine |
| sulfadiazin silber |
| thermazene |
| n(sup 1)-2-pyrimidinylsulfanilamide monosilver(1+) salt |
| silver sulfafdiazine |
| S0595 |
| AKOS005111099 |
| NCGC00183137-01 |
| silver(i) sulfadiazine |
| tox21_113471 |
| cas-22199-08-2 |
| tox21_112998 |
| dtxsid4048646 , |
| dtxcid1028572 |
| unii-w46jy43ejr |
| sulfadiazine, silver [usan:usp] |
| w46jy43ejr , |
| (4-amino-n-2-pyrimidinylbenzenesulfonamidato-nn,01)-silver |
| FT-0630481 |
| CHEMBL1382627 |
| silvazine |
| altreet-ag |
| sulfadiazinum argentum |
| sulfadiazine silver [who-dd] |
| silver sulfadiazine [orange book] |
| sulfadiazine silver [mart.] |
| sulfadiazine silver [who-ip] |
| sulfadiazine, silver [usp impurity] |
| silver sulfadiazine [green book] |
| sulfadiazine silver salt [mi] |
| benzenesulfonamide, 4-amino-n-2-pyrimidinyl-, silver(1+) salt (1:1) |
| silver sulfadiazine [usp monograph] |
| silver sulfadiazine [usp-rs] |
| silver, (4-amino-n-(2-pyrimidinyl-.kappa.n1)benzenesulfonamidato-.kappa.o)- |
| silver sulfadiazine [vandf] |
| sulfadiazine silver [jan] |
| 1152234-18-8 |
| sulfadiazinum argentum [who-ip latin] |
| SCHEMBL15633 |
| J-014582 |
| silver(1+) ion 4-{[(pyrimidin-2-yl)azanidyl]sulfonyl}aniline |
| Q420984 |
| mfcd00072101 |
| SY105573 |
| silver sulfadiazine usp |
| 4-amino-n-(2-pyrimidinyl) benzenesulfonamide silver salt |
| silver (i) sulfadiazine |
| silver(i) ((4-aminophenyl)sulfonyl)(pyrimidin-2-yl)amide |
| AS-13863 |
| silver;(4-aminophenyl)sulfonyl-pyrimidin-2-ylazanide |
| silver sulfadiazine bulk powder |
| silver, (4-amino-n-(2-pyrimidinyl-kappan1)benzenesulfonamidato-kappao)- |
| sliverex |
| sulfadiazine, silver (usan:usp) |
| sulfadiazine, silver (usp impurity) |
| sulfadiazine silver (mart.) |
| thermazenesilver sulfadiazine |
| rayasore kit |
| silver sulfadiazine (usp monograph) |
| silver(1+) ((4-aminophenyl)sulfonyl)(pyrimidin-2-yl)azanide |
| silver sulfadiazene |
| silver sulfadazine |
| monosilver 4-amino-n-(pyrimidin-2-yl)benzenesulfonamidate |
| silver sulfadiazine (usp-rs) |
| ssd cream |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Role | Description |
|---|---|
| antimicrobial agent | A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
| antibacterial drug | A drug used to treat or prevent bacterial infections. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| silver salt | |
| sulfonamidate | |
| pyrimidines | Any compound having a pyrimidine as part of its structure. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 6.6838 | 0.0008 | 11.3822 | 44.6684 | AID686979 |
| AR protein | Homo sapiens (human) | Potency | 4.9582 | 0.0002 | 21.2231 | 8,912.5098 | AID743053 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 30.0474 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 29.8493 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Replicase polyprotein 1ab | Betacoronavirus England 1 | IC50 (µMol) | 10.0000 | 0.0040 | 3.4388 | 9.5100 | AID1640022 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 (µMol) | 0.7500 | 0.0002 | 2.4585 | 9.9600 | AID1640021 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID625279 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625283 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625285 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625282 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625281 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625292 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1275018 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 in porcine deep partial thickness wound infection model assessed as decrease in bacterial burden in wound using compound in form of 1% cream treated within 20 mins measured 24 hrs post infe | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Identification of novel cyclic lipopeptides from a positional scanning combinatorial library with enhanced antibacterial and antibiofilm activities. |
| AID625290 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625288 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625289 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625284 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625287 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625280 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625291 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625286 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (69.70) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomised Clinical Study to Evaluate the Use of Tilapia Skin (Oreochromis Niloticus), as an Occlusive Biological Dressing, in the Treatment of Burn Wounds [NCT03592498] | Phase 2 | 63 participants (Actual) | Interventional | 2016-10-05 | Completed | ||
| A Randomized Controlled Clinical Trial Comparing The Efficacy and Safety of Open Dressing With Petrolatum Jelly vs. Standard Gauze Dressing With Silver Sulfadiazine in the Treatment of Filipino Adults Aged 18-45 Years Old With Superficial Partial Thicknes [NCT02109718] | Phase 3 | 50 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240] | Early Phase 1 | 11 participants (Actual) | Interventional | 2014-03-06 | Terminated(stopped due to Not enough patient enrollment and lack of staffing) | ||
| Phase I/II Clinical Trial Randomized, Multicentric, Open Label, Standard of Care (Silver Sulfadiazine) Controlled Aiming at Assessing Tolerance and Efficacy of Local Bacteriophage Treatment of Wound Infections Due to E. Coli or P. Aeruginosa in Burned Pat [NCT02116010] | Phase 1/Phase 2 | 0 participants | Interventional | 2015-07-31 | Recruiting | ||
| Effectiveness of KeraStat Gel for Improved Cosmesis of Partial Thickness Burns [NCT03564795] | 30 participants (Anticipated) | Interventional | 2018-08-31 | Recruiting | |||
| Comparative Analysis of Cost-effectiveness of Silver Dressing in Burns [NCT02108535] | Phase 4 | 100 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Evaluation of a Management Strategy for Second-degree Fibrinous Burns Integrating a Poly-absorbent Dressing: a Prospective, Controlled, Open, Randomized Multicentre Study [NCT05347654] | 310 participants (Anticipated) | Interventional | 2023-01-20 | Recruiting | |||
| Topical Collagen-Silver Versus Standard Care Following Phenol Ablation of Ingrown Nails: A Randomized Controlled Trial [NCT00641433] | 80 participants (Anticipated) | Interventional | 2005-11-30 | Recruiting | |||
| Randomized Controlled Trial Assessing a Novel Glycopolymer Compound in the Treatment of Superficial Partial-Thickness Burns [NCT05877638] | 115 participants (Anticipated) | Interventional | 2023-03-27 | Recruiting | |||
| Drainage of Subglottic Secretions and Prevention of Ventilator-associated Pneumonia in Intensive carE Units: Medico-Economic Study With a Randomized clusTer and crossovER Design: DEMETER Study [NCT02515617] | 2,577 participants (Actual) | Interventional | 2015-11-05 | Completed | |||
| A Randomized Intra-Patient Controlled Study of StrataXRT ® Versus Current Practice to Prevent and Treat Radiation Dermatitis [NCT05073172] | 92 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
| Detection of Chlorhexidine in Tracheal Secretions After Routine Oral Care With Chlorhexidine Gluconate: an Ancillary Study of the DEMETER Trial (NCT02515617) [NCT02583321] | 66 participants (Actual) | Interventional | 2015-11-04 | Completed | |||
| Subglottic Secretions Surveillance to Predict Bacterial Pathogens Involved in Ventilator-associated Pneumonia (VAP): an Ancillary Study of the DEMETER Trial (NCT02515617) [NCT02585180] | 420 participants (Actual) | Interventional | 2015-11-04 | Completed | |||
| Impact of the Subglottic Secretions Drainage on the Tracheal Secretions Colonisation: an Ancillary Study of the DEMETER Trial (NCT02515617) [NCT02583308] | 896 participants (Actual) | Interventional | 2015-11-04 | Completed | |||
| A Phase 2, Open-Label, Randomized, Active-Controlled Pilot Study of Investigational Drug, MW-III Versus Silvadene® Cream 1% (Silver Sulfadiazine) Topically Applied to Second-Degree Thermal Burns in Adults [NCT01297400] | Phase 2 | 60 participants (Anticipated) | Interventional | 2022-03-11 | Recruiting | ||
| Can Silversulfadiazine Prevent Pin-site Infection in Open Tibial Fracture?: A Randomized Controlled Trial [NCT01017094] | Phase 3 | 30 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Evaluation of Nile Tilapia (Oreochromis Niloticus) Skin as an Occlusive Biological Dressing in the Treatment of Burn Wounds: Phase III Randomized Controlled Trial [NCT04202289] | Phase 3 | 115 participants (Actual) | Interventional | 2017-04-03 | Completed | ||
| An Open, Parallel, Randomized, Comparative, Multi-centre Investigation in US Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex® Ag Versus Silvadene® in the Treatment of Partial Thickness Burns. [NCT00742183] | 100 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
| Randomized Controlled Trial Assessing a Novel Glycopolymer Compound in the Treatment of Superficial Partial-thickness Burns [NCT04601532] | Phase 4 | 115 participants (Anticipated) | Interventional | 2021-06-11 | Recruiting | ||
| The Effect of Two Versus Ten Days Application of Flammacerium in Partial Thickness Burns [NCT00156988] | Phase 4 | 0 participants | Interventional | 2004-03-31 | Completed | ||
| A Randomised Multicentre Clinical Trial on the Efficacy of Flammacerium in the Treatment of Facial Burns and the Impact of Facial Burns on Psychosocial Wellbeing [NCT00297752] | Phase 4 | 154 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Phase II Study Designed to Evaluate the Value of Neoviderm Skin Emulsion in the Prevention of Radiation Dermatitis for Patients Undergoing External Radiation Therapy [NCT01701466] | Phase 2 | 14 participants (Actual) | Interventional | 2011-12-31 | Terminated | ||
| The Clinical Efficacy of Epidermal Growth Factor With Silver Sulfadiazine Cream Compared With Silver Zinc Sulfadiazine Cream on Acceleration of Partial Thickness Burn Wound Healing [NCT01553708] | Phase 2/Phase 3 | 34 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| A Prospective Randomized Trial Comparing Silver Sulfadiazine Cream to a Water-Soluble Poly-Antimicrobial Gel in Partial Thickness Burn Wounds [NCT01926392] | Phase 4 | 8 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Pediatric Burn Treatment Using Tilapia Skin as a Xenograft for Superficial-Partial Thickness Wounds: a Randomized Controlled Phase II Trial [NCT04391582] | Phase 2 | 30 participants (Actual) | Interventional | 2017-05-01 | Completed | ||
| To Study the Healing Effect of Silver Impregnated Activated Carbon Fiber Wound Dressing on Superficial Dermal Burn [NCT01598480] | 30 participants (Actual) | Interventional | 2012-05-31 | Completed | |||
| To Study the Healing Effect of Silver Impregnated Activated Carbon Fiber Wound Dressing on Deep Dermal Burn [NCT01598493] | 30 participants (Actual) | Interventional | 2012-05-31 | Completed | |||
| Comparison Study OF Efficacy Of Autologous Epidermal Cell Suspension And Silver Sulfadiazine Ointment In Second Degree Burn [NCT03162367] | Phase 2 | 40 participants (Actual) | Interventional | 2019-04-10 | Completed | ||
| An Open, Randomized, Comparative, Multi-centre Investigation Evaluating the Efficacy and Tolerance of Mepilex Ag Versus Silver Sulfadiazine in the Treatment of Deep Partial Thickness Burn Injuries. [NCT01439074] | 162 participants (Actual) | Interventional | 2011-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||